Cancers, Vol. 15, Pages 4361: The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting & mdash;A Nation-Wide Retrospective Analysis (RACER)

Cancers, Vol. 15, Pages 4361: The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER) Cancers doi: 10.3390/cancers15174361 Authors: Paweł Michał Potocki Rafał Wiśniowski Dominik Haus Zbyszko Chowaniec Maciej Kozaczka Magdalena Kustra Marzenna Samborska-Plewicka Marcin Szweda Danuta Starzyczny-Słota Magdalena Michalik Grzegorz Słomian Aneta Lebiedzińska Natalia Jonak-Olczyk Natalia Łaszewska-Kraińska Krzysztof Adamowicz Piotr Kolenda Anna Drosik-Kwaśniewska Marek Szwiec Robert Dziura Justyna Czech Maria Dąbrowska Ewa Nowakowska-Zajdel Ewa Klank-Sokołowska Kamil Konopka Łukasz Kwinta Jolanta Dobrzańska Piotr J. Wysocki Anti-EGFR antibodies combined with chemotherapy doublets are a cornerstone of the upfront treatment of colorectal cancer. RAS and BRAF mutations are established negative predictive factors for such therapy. The primary tumour located in the proximal colon has recently emerged as another negative predictive factor. We have conducted a retrospective multicentre study to collect data on real-world population characteristics, practice patterns, and outcomes in patients with metastatic colorectal cancer treated in a first-line setting with either cetuximab or panitumumab in combination with either FOLFOX or FOLFIRI chemotherapy. The presented analysis focu...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research